Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NXPPXVZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMECwOFU5KG6P NYTMfVBkW0GQR1XS
ES4 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:xSJZKSzVyPUCuNFAxPjV|IH7N MlHmV2FPT0WU
ACHN MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPwbHJKSzVyPUCuNFAxQDh5IH7N MXnTRW5ITVJ?
KYSE-510 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMECwPVc2KG6P NX;Q[lZ{W0GQR1XS
EW-7 M2WxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C1OWlEPTB;MD6wNFI2QCCwTR?= NUnxVHRIW0GQR1XS
BFTC-905 M4rpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33ON2lEPTB;MD6wNFUyPSCwTR?= MVzTRW5ITVJ?
KE-37 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq2V4pKUUN3ME2wMlAxPTZzIH7N NIjpPG1USU6JRWK=
SBC-5 NHq3bIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[4NVRXUUN3ME2wMlAxPTdibl2= NGDu[4xUSU6JRWK=
NKM-1 M37SbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OyfWlEPTB;MD6wNFcxQSCwTR?= MVfTRW5ITVJ?
RH-1 NF2wdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEC3NVghdk1? NFT3Ro1USU6JRWK=
ALL-PO M4jFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrYTWM2OD1yLkCwPFMhdk1? MXHTRW5ITVJ?
QIMR-WIL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7lbI5KSzVyPUCuNFA5QTRibl2= M{ewSnNCVkeHUh?=
A375 M2TPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rVfGlEPTB;MD6wNFk6PSCwTR?= NXTHZ3h[W0GQR1XS
SIG-M5 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEGwOEBvVQ>? NXTzZVZQW0GQR1XS
KGN M37VVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrxeVhKSzVyPUCuNFExQCCwTR?= MorvV2FPT0WU
EW-13 NFP0fmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEGxNkBvVQ>? M4nHVHNCVkeHUh?=
NCI-SNU-1 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFTWM2OD1yLkCxOkBvVQ>? NXHTdnk3W0GQR1XS
PSN1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEG2OUBvVQ>? M3XzO3NCVkeHUh?=
HUTU-80 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEG2OkBvVQ>? NGLKR3hUSU6JRWK=
EW-16 NHvCTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{npU2lEPTB;MD6wNlMhdk1? MWDTRW5ITVJ?
786-0 NWGyT3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{naOWlEPTB;MD6wNlMhdk1? NYD3[Hh{W0GQR1XS
ES1 NYPHbop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK5fWhKSzVyPUCuNFI3QCCwTR?= MULTRW5ITVJ?
RKO NXLFWnc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ITWM2OD1yLkCyO|khdk1? MXPTRW5ITVJ?
ESS-1 M1r6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEK4OkBvVQ>? MofvV2FPT0WU
SK-UT-1 NITDOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4[WlEPTB;MD6wNlk4KG6P MXrTRW5ITVJ?
LB2241-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfnNmNEUUN3ME2wMlA{OThibl2= MlXPV2FPT0WU
CHL-1 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEOyOEBvVQ>? MX3TRW5ITVJ?
SW1783 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TxfGlEPTB;MD6wN|M3KG6P MnnRV2FPT0WU
MEL-JUSO NX7IXoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjsZpZVUUN3ME2wMlA{QTFibl2= NHPISY1USU6JRWK=
HT-29 NFvqfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrGTWM2OD1yLkC0NVMhdk1? NEPDeWpUSU6JRWK=
SNG-M M2TX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkTWM2OD1yLkC0NlUhdk1? MYDTRW5ITVJ?
TE-15 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofDTWM2OD1yLkC0OlQhdk1? MVnTRW5ITVJ?
HOS MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL1TWM2OD1yLkC0PEBvVQ>? MYDTRW5ITVJ?
BB65-RCC MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmzdoVKSzVyPUCuNFUyOiCwTR?= MVXTRW5ITVJ?
HCE-4 NH7GOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nxeWlEPTB;MD6wOVI5KG6P NFnBS|NUSU6JRWK=
MHH-ES-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n6U2lEPTB;MD6wOVMyKG6P M3e2RnNCVkeHUh?=
RPMI-7951 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEW0NUBvVQ>? MoLPV2FPT0WU
IST-SL2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTzTWM2OD1yLkC1PFQhdk1? M3j5XXNCVkeHUh?=
CMK NXe4TlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIez[nlKSzVyPUCuNFU5PiCwTR?= MX;TRW5ITVJ?
GR-ST MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i0VWlEPTB;MD6wOVk2KG6P NEDXSIhUSU6JRWK=
NALM-6 NU\2UlZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHQR5RyUUN3ME2wMlA3OjJibl2= NXnJWJkxW0GQR1XS
RPMI-6666 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zXR2lEPTB;MD6wOlUzKG6P M3nHeHNCVkeHUh?=
LC-2-ad NXu4b3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPhXYZKSzVyPUCuNFY2OyCwTR?= M4DJSXNCVkeHUh?=
ARH-77 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TMdmlEPTB;MD6wO|EyKG6P NF3keIZUSU6JRWK=
IST-MEL1 M13S[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrhZ2RWUUN3ME2wMlA4OjZibl2= MVLTRW5ITVJ?
SW1710 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP5TWM2OD1yLkC3OVEhdk1? MY\TRW5ITVJ?
DEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe4ZZB{UUN3ME2wMlA5QDdibl2= MWPTRW5ITVJ?
AGS NUHWfGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW0Xm1KSzVyPUCuNFkxOiCwTR?= M4q4VHNCVkeHUh?=
NCI-H2122 NUS4SId{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXWUJBKSzVyPUCuNFk1PiCwTR?= MmDjV2FPT0WU
HSC-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3vd|VKSzVyPUCuNVAzKG6P MnfoV2FPT0WU
AM-38 NHvG[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvBeYFrUUN3ME2wMlEzOSCwTR?= MljoV2FPT0WU
769-P NIfvU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHSTWM2OD1yLkGyN{BvVQ>? NV\BblQyW0GQR1XS
RT-112 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0TWM2OD1yLkGyO{BvVQ>? NF35SZpUSU6JRWK=
MCF7 NW[0W5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTuUW5CUUN3ME2wMlE{PiCwTR?= NF3EN3BUSU6JRWK=
IGROV-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi3dnBQUUN3ME2wMlE1PSCwTR?= NUfTe5Z4W0GQR1XS
OCI-AML2 M4jhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTWVm5EUUN3ME2wMlE1PyCwTR?= NHjDd21USU6JRWK=
NCI-H1299 NEHETYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUW3JI5O MYfTRW5ITVJ?
A431 NFTBXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\iUpZqUUN3ME2wMlE5OyCwTR?= MVHTRW5ITVJ?
SW982 NEXB[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\QPWlEPTB;MD6yNVMhdk1? MknGV2FPT0WU
BB30-HNC Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWxTWM2OD1yLkKzNUBvVQ>? NEHmXYlUSU6JRWK=
ACN M4S4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxRoxKSzVyPUCuNlQ1KG6P NWj0S|E4W0GQR1XS
647-V NUXaRWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nqfWlEPTB;MD6yOFghdk1? MWLTRW5ITVJ?
SK-PN-DW NE[2dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPV[VZKSzVyPUCuNlY3KG6P NFfnRYxUSU6JRWK=
LCLC-97TM1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzVVnZWUUN3ME2wMlI3PyCwTR?= NIPyco9USU6JRWK=
LB1047-RCC Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXjSmFKSzVyPUCuNlY6KG6P NIi0cIhUSU6JRWK=
A2780 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M330cWlEPTB;MD6yO{BvVQ>? NX76U|hoW0GQR1XS
C-33-A NUP3UIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1yLkK3N{BvVQ>? MoTlV2FPT0WU
NCI-H2228 NH\wNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq0UHVKSzVyPUCuN|E1KG6P NXHkTHVGW0GQR1XS
TE-5 NF;CR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7BTWM2OD1yLkOxOkBvVQ>? M3HCVnNCVkeHUh?=
HC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrVdGxKSzVyPUCuN|I4KG6P MXfTRW5ITVJ?
SK-MES-1 NWDpeYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnWO4hUUUN3ME2wMlMzQCCwTR?= NYHycoxrW0GQR1XS
NCI-H1355 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj3O5FIUUN3ME2wMlM5OSCwTR?= NHTVU3pUSU6JRWK=
YKG-1 NVPBZ4tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNEG5JI5O Mn\sV2FPT0WU
RS4-11 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhR3JKSzVyPUCuOFM{KG6P NXLw[nFTW0GQR1XS
Daoy MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[xU2lEPTB;MD60OVYhdk1? MoDwV2FPT0WU
A3-KAW NIHEbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC1TWM2OD1yLkW1NUBvVQ>? MX;TRW5ITVJ?
SK-MEL-30 M{nCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfrSlFKSzVyPUCuOVU1KG6P MX\TRW5ITVJ?
U031 M1PEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\X[WNyUUN3ME2wMlU3PSCwTR?= MXfTRW5ITVJ?
SK-LMS-1 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmryTWM2OD1yLkW3PEBvVQ>? MV7TRW5ITVJ?
ES6 NHXqUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDQbmNKSzVyPUCuOVg3KG6P NYj0dpI3W0GQR1XS
EoL-1-cell NW\OOldkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\6TWM2OD1yLk[xOkBvVQ>? MVfTRW5ITVJ?
NCI-H2009 NHXwbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iyR2lEPTB;MD62NVkhdk1? NWLmOph5W0GQR1XS
A4-Fuk NY\ZVZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNkK2JI5O NVvRTnNtW0GQR1XS
KYSE-270 M1\NW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD1yLk[zOEBvVQ>? MlXZV2FPT0WU
SK-LU-1 M13wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNkW1JI5O NETNXWpUSU6JRWK=
SW872 NX;3NJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH6W2lKSzVyPUCuO|Y2KG6P NYricnBXW0GQR1XS
ES8 M3r0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwN{igcm0> NUfES5puW0GQR1XS
G-402 NHrP[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPYbY1uUUN3ME2wMlc5PCCwTR?= NYPCeYF{W0GQR1XS
ATN-1 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SySmlEPTB;MD64NFchdk1? NXnKS4FoW0GQR1XS
DoTc2-4510 NEH0SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXm[oZKSzVyPUCuPVAyKG6P M1f6N3NCVkeHUh?=
MES-SA M1XLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jue2lEPTB;MD65NFUhdk1? NF;sN2ZUSU6JRWK=
SF268 NUPwcGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvyVpNQUUN3ME2wMlkzPyCwTR?= NX;abGQ1W0GQR1XS
SF539 NWPJV|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1zLkCyJI5O MmPNV2FPT0WU
NB69 M{DXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DvUGlEPTB;MT6wOUBvVQ>? MXrTRW5ITVJ?
8505C NGDqbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v6UmlEPTB;MT6wOkBvVQ>? M{PxVnNCVkeHUh?=
CAL-12T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQRWNKSzVyPUGuNFghdk1? NEO3dVFUSU6JRWK=
BHY Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMUSgcm0> MXnTRW5ITVJ?
LB647-SCLC MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe3WopKSzVyPUGuNVghdk1? MX;TRW5ITVJ?
CAL-62 NILqXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHzWpdKSzVyPUGuNlIhdk1? MlzCV2FPT0WU
MEG-01 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMkegcm0> NUnDVJdUW0GQR1XS
MG-63 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13SO2lEPTB;MT6zN{BvVQ>? MVrTRW5ITVJ?
SW620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrTZ25rUUN3ME2xMlM2KG6P NGDmNnhUSU6JRWK=
A388 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD1zLkO2JI5O MmjqV2FPT0WU
BCPAP NFTMWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne2TWM2OD1zLkS1JI5O M{X5bnNCVkeHUh?=
P30-OHK MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ET5ZKUUN3ME2xMlQ3KG6P MXnTRW5ITVJ?
Ca9-22 NFPpdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP2RVU5UUN3ME2xMlU1KG6P NIn1fotUSU6JRWK=
VMRC-RCZ NFPUd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwNUSgcm0> NIfzO5VUSU6JRWK=
LOXIMVI MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\WTWM2OD1zLk[gcm0> NI\h[FVUSU6JRWK=
L-540 M{LHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3vemNKSzVyPUGuOkBvVQ>? MVHTRW5ITVJ?
NTERA-S-cl-D1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm0Z3VkUUN3ME2xMlY1KG6P MWDTRW5ITVJ?
MFH-ino MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTNTWM2OD1zLk[2JI5O MU\TRW5ITVJ?
Calu-6 M{DrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki4TWM2OD1zLkezJI5O MnjtV2FPT0WU
HEL MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwN{mgcm0> MVPTRW5ITVJ?
CAL-33 M3LGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDwXlFKSzVyPUGuPFkhdk1? MoTZV2FPT0WU
HSC-3 NULiW3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwOUGgcm0> MU\TRW5ITVJ?
KU812 M3HBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDXZotbUUN3ME2xMlkyKG6P MmHMV2FPT0WU
EB2 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHpVYZKSzVyPUKuNFEhdk1? MnXBV2FPT0WU
SR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\seWlEPTB;Mj6xNkBvVQ>? NXrHcmFMW0GQR1XS
NCI-H2087 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPOTWM2OD1{LkG0JI5O NHHZWG5USU6JRWK=
H4 NEW3cXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nHdGlEPTB;Mj6xPEBvVQ>? MUfTRW5ITVJ?
EW-1 NUXObYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRdFd7UUN3ME2yMlIzKG6P NGnSSmRUSU6JRWK=
MC-IXC MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzueZVKSzVyPUKuNlYhdk1? NVfYdHFZW0GQR1XS
NCI-H727 M33kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3XGFSUUN3ME2yMlUyKG6P NXjrPVJzW0GQR1XS
MRK-nu-1 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjiTWM2OD1{LkW3JI5O MYTTRW5ITVJ?
COLO-668 M{XiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61cGRXUUN3ME2yMlY3KG6P Mk\XV2FPT0WU
CGTH-W-1 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HEeGlEPTB;Mj63NkBvVQ>? NIPK[HVUSU6JRWK=
CHP-212 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rTc2lEPTB;Mj63OUBvVQ>? NHLTPYVUSU6JRWK=
GI-1 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofyTWM2OD1{Lke2JI5O M{jQR3NCVkeHUh?=
HCC1806 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwOUGgcm0> M1T0enNCVkeHUh?=
HLE NXHIe5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DCU2lEPTB;MzDuUS=> M1P6fHNCVkeHUh?=
HSC-2 NFPzVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK3TWM2OD1|LkCzJI5O M4jUR3NCVkeHUh?=
DMS-273 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe1OHRKSzVyPUOuNFchdk1? NF;IfFdUSU6JRWK=
DU-4475 NFvoTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD1|LkG0JI5O MnnwV2FPT0WU
LXF-289 M3HNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XqN2lEPTB;Mz6zNUBvVQ>? NG\K[4ZUSU6JRWK=
PANC-03-27 NU\obWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7sUWpKSzVyPUOuOVEhdk1? NISzfllUSU6JRWK=
GAMG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjqe|V3UUN3ME2zMlc1KG6P M{TFdHNCVkeHUh?=
NCI-H522 NIe4TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jFS2lEPTB;ND6zOEBvVQ>? M{[0XXNCVkeHUh?=
SW626 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;6cYZKSzVyPUSuOFYhdk1? NEizUW9USU6JRWK=
HT-144 NFLPWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrIXoZNUUN3ME20MlkzKG6P NUD1WndMW0GQR1XS
MEL-HO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4OYNzUUN3ME21MlE3KG6P NWnm[4tbW0GQR1XS
BE-13 NXHKSXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwMkGgcm0> MWjTRW5ITVJ?
VA-ES-BJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTVwMk[gcm0> NGXsc29USU6JRWK=
NCI-H441 NGPBRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL3SVhzUUN3ME21MlYhdk1? MmjsV2FPT0WU
KP-4 M4ToXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTVwNkGgcm0> NYTkV2x6W0GQR1XS
LoVo M4ntXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTVwN{Ggcm0> NGLvWJVUSU6JRWK=
HT-1080 M2Plfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LadmlEPTB;NT64N{BvVQ>? MkHVV2FPT0WU
GB-1 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTVwOESgcm0> NVzrfFY4W0GQR1XS
IA-LM MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4UndKSzVyPUWuPVEhdk1? NYLOeGxFW0GQR1XS
8-MG-BA MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\zeo1KSzVyPUWuPVMhdk1? MknGV2FPT0WU
SK-HEP-1 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwMUSgcm0> NGn4dGZUSU6JRWK=
697 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TDSGlEPTB;Nj6yOUBvVQ>? NUnK[XJPW0GQR1XS
KYSE-450 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZwM{Kgcm0> M3n6c3NCVkeHUh?=
HCC2998 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36w[WlEPTB;Nj6zOEBvVQ>? MUnTRW5ITVJ?
HD-MY-Z NF6wUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDTPG02UUN3ME22MlY5KG6P M37penNCVkeHUh?=
OS-RC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTZwNkigcm0> Mk\LV2FPT0WU
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV72ZoFVUUN3ME23MlA2KG6P NFv0ZY5USU6JRWK=
Ca-Ski NILoRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD5WY9KSzVyPUeuNFkhdk1? MWXTRW5ITVJ?
NCI-H358 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEPGlEPTB;Nz6xOkBvVQ>? NXvuU|ZtW0GQR1XS
J82 NWnjSmVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\iTWM2OD15LkSxJI5O NXvxcFJRW0GQR1XS
NCI-H2342 M3HUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHXXGhKSzVyPUeuOlMhdk1? MlTzV2FPT0WU
OVCAR-8 NV7qdmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\MTWM2OD15Lkmgcm0> MnXsV2FPT0WU
TE-8 NWfVN4prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\qTWM2OD16IH7N NXjzWGdrW0GQR1XS
ETK-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7p[FVyUUN3ME24MlA5KG6P M4nYfXNCVkeHUh?=
HAL-01 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r4eGlEPTB;OD6yJI5O NHezWItUSU6JRWK=
KYSE-150 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRThwNEegcm0> NH\Xc2tUSU6JRWK=
NCI-H810 NYHB[ItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;0cWFxUUN3ME24MlU3KG6P Mo\yV2FPT0WU
ONS-76 NUC3THRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D0WWlEPTB;OD62PEBvVQ>? M{jUd3NCVkeHUh?=
NMC-G1 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwN{[gcm0> MYjTRW5ITVJ?
C3A NGe5W4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHLbXlKSzVyPUiuPFQhdk1? NIDRSm1USU6JRWK=
PA-1 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W0VGlEPTB;OD65PUBvVQ>? Mk\EV2FPT0WU
SH-4 NX3lO3Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTlwMEKgcm0> MWLTRW5ITVJ?
EFO-27 NYf1UnJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTidG05UUN3ME25MlA2KG6P MUPTRW5ITVJ?
CAPAN-1 M3;4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zMWmlEPTB;OT6yN{BvVQ>? NEn5Z4ZUSU6JRWK=
DU-145 NWO3XWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTlwMkmgcm0> MULTRW5ITVJ?
A101D NYrsVGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCSlI4UUN3ME25MlM4KG6P M2LwNHNCVkeHUh?=
ST486 NHrk[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfkTWM2OD17LkSxJI5O MUfTRW5ITVJ?
NCI-H1437 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXxcmNKSzVyPUmuOFIhdk1? Mlu3V2FPT0WU
HGC-27 NIK1dIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPrV3FiUUN3ME25MlYhdk1? MYPTRW5ITVJ?
8305C MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfEV2tKSzVyPUmuOlQhdk1? NFW5VFdUSU6JRWK=
OCUB-M M4XSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnMTWM2OD1zMD6wN{BvVQ>? NFS0S2xUSU6JRWK=
COLO-679 M2TxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhRYJKSzVyPUGwMlA4KG6P NGHucFJUSU6JRWK=
Detroit562 NVXqUFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzpeWlxUUN3ME2xNE41OiCwTR?= MmHWV2FPT0WU
A204 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj1TWM2OD1zMT6xOkBvVQ>? NIi3RmZUSU6JRWK=
NCI-H1734 NVm2N|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLkK5JI5O NXTxR|ZEW0GQR1XS
MC-CAR NHnZSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLyVWV4UUN3ME2xNU42QCCwTR?= NH7pflVUSU6JRWK=
NCI-H2170 NHHDZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\JTWM2OD1zMT65O{BvVQ>? NYjwTGZZW0GQR1XS
NCI-SNU-5 NHX6RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknsTWM2OD1zMj6xN{BvVQ>? M2PoRnNCVkeHUh?=
HCE-T MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\KTmdKSzVyPUGyMlQzKG6P NF3Lco5USU6JRWK=
KYSE-180 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XLN2lEPTB;MUKuPFEhdk1? M4LyPXNCVkeHUh?=
C8166 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\kTWM2OD1zMz6wPEBvVQ>? M4HB[nNCVkeHUh?=
NCI-H460 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzYUHlKSzVyPUGzMlU1KG6P M{XHXnNCVkeHUh?=
SNU-449 M4DnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXtWW1ZUUN3ME2xN{44PyCwTR?= Mo\pV2FPT0WU
MDA-MB-468 M{HUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X5cWlEPTB;MUSuNVIhdk1? NFz5OVRUSU6JRWK=
COR-L23 M{nCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO3TWM2OD1zND6xN{BvVQ>? NFPLU|JUSU6JRWK=
CTV-1 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiy[4VKSzVyPUG0MlE1KG6P NUTyc5ljW0GQR1XS
BL-41 NYGxTW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLRTWM2OD1zND6zO{BvVQ>? MlHNV2FPT0WU
IGR-1 M2nRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly1TWM2OD1zND60NkBvVQ>? NF\vWVVUSU6JRWK=
TK10 NVK3T4RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWUFZHUUN3ME2xOE41QSCwTR?= M2\VbXNCVkeHUh?=
REH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2LkWxJI5O Mo\IV2FPT0WU
LU-139 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZ[mlEPTB;MUSuOVkhdk1? MoX2V2FPT0WU
KP-N-YS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;kUWlEPTB;MUSuPVchdk1? NW\BOWRwW0GQR1XS
PANC-10-05 NWPaSoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJ[|dKSzVyPUG1MlM5KG6P MVrTRW5ITVJ?
HL-60 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlSyTWM2OD1zNT62PUBvVQ>? NETzenRUSU6JRWK=
T84 NWG1cW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXFbVNKSzVyPUG1Mlk3KG6P NHjwVmZUSU6JRWK=
RPMI-8226 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrKTYlvUUN3ME2xOk4xOiCwTR?= MUnTRW5ITVJ?
UM-UC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm5TWM2OD1zNj6xOkBvVQ>? MXLTRW5ITVJ?
TE-10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TIZmlEPTB;MU[uNlEhdk1? MoHRV2FPT0WU
CAL-148 NUjjOGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrITWM2OD1zNz6yN{BvVQ>? NVvYOGM2W0GQR1XS
BV-173 NVrheZRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF5LkK3JI5O M{LEOHNCVkeHUh?=
Calu-3 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF5LkK5JI5O M4HNPHNCVkeHUh?=
RPMI-2650 NH7vV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF5LkW5JI5O M{\SXHNCVkeHUh?=
MKN45 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5LkezJI5O NGjxTXhUSU6JRWK=
NUGC-3 M4DNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnpOGw1UUN3ME2xPE4{PCCwTR?= MknyV2FPT0WU
NCI-H520 NXXL[ItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzhW2t3UUN3ME2xPE44PyCwTR?= MV\TRW5ITVJ?
CCRF-CEM NHjlXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYZ|BMUUN3ME2xPE45PSCwTR?= NYfVUmZnW0GQR1XS
NCI-H2405 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TTe2lEPTB;MUmuNUBvVQ>? NHTYbZBUSU6JRWK=
ES7 NFXNU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC1TWM2OD1zOT63OkBvVQ>? MXrTRW5ITVJ?
BPH-1 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6UHozUUN3ME2yNE4zQCCwTR?= M3HRN3NCVkeHUh?=
SAS NX[wZmRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzrc4ZKSzVyPUKwMlUhdk1? M{HyXnNCVkeHUh?=
HuCCT1 NVLSfYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXOTWM2OD1{MD61PEBvVQ>? MlKyV2FPT0WU
LOUCY MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\xe3dWUUN3ME2yNE43PiCwTR?= M1[1PXNCVkeHUh?=
NCI-H292 M3XTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq3[nQxUUN3ME2yNE44QSCwTR?= MYLTRW5ITVJ?
G-361 NH7jTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJzLkC3JI5O MUfTRW5ITVJ?
M059J MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[4boFWUUN3ME2yNU4xQCCwTR?= NUTodVI4W0GQR1XS
NCI-H1651 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnF[lhKSzVyPUKxMlEyKG6P MmfXV2FPT0WU
KALS-1 NHrFV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\WTWM2OD1{MT6zPUBvVQ>? M3iyWXNCVkeHUh?=
DJM-1 M3vNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vxXWlEPTB;MkGuOVkhdk1? M3fKSnNCVkeHUh?=
AU565 NHGzS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GyWmlEPTB;MkGuPFMhdk1? MknlV2FPT0WU
HCC38 NXjGUoJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPmb|JKSzVyPUKxMlk2KG6P M1PkRnNCVkeHUh?=
U251 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ{LkK3JI5O M2XkN3NCVkeHUh?=
ABC-1 M2LYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXBXnJyUUN3ME2yNk43PSCwTR?= MYfTRW5ITVJ?
SK-NEP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TzOmlEPTB;MkKuPVMhdk1? NIfVVZlUSU6JRWK=
CESS NGPxVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ|LkG5JI5O NG\Re2ZUSU6JRWK=
MIA-PaCa-2 M2Lpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ|LkO2JI5O NGG4[VRUSU6JRWK=
SUP-T1 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvpfYJKSzVyPUKzMlQ4KG6P NVzJPVNXW0GQR1XS
L-428 NFrpV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLMS4NKSzVyPUKzMlYzKG6P NYrwdXM3W0GQR1XS
SW954 M3\FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnqXm1KSzVyPUKzMlY5KG6P NV7oVnFqW0GQR1XS
HO-1-N-1 NGLKflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fuUWlEPTB;MkOuO|chdk1? MYXTRW5ITVJ?
CHP-126 NYPTXW85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LodGlEPTB;MkSuNVQhdk1? MWPTRW5ITVJ?
HMV-II M3nLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTnTWM2OD1{ND6zOEBvVQ>? MX3TRW5ITVJ?
NB10 M1exfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjITWM2OD1{ND6zO{BvVQ>? NETMcFdUSU6JRWK=
A172 NF6yUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTDTWM2OD1{ND63NUBvVQ>? M3fFZXNCVkeHUh?=
MONO-MAC-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ2Lki0JI5O M37lenNCVkeHUh?=
NCI-H1650 NITxWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ3LkSgcm0> MmHEV2FPT0WU
NH-12 NUmy[ng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XsSmlEPTB;MkWuOUBvVQ>? M4r1XnNCVkeHUh?=
ML-2 NGTUUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7hTWM2OD1{NT63OEBvVQ>? M4jnT3NCVkeHUh?=
MZ2-MEL Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fzR2lEPTB;Mk[uNlIhdk1? NH7od4ZUSU6JRWK=
COLO-684 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDhTWM2OD1{Nj60NUBvVQ>? M2\KUXNCVkeHUh?=
HuP-T4 NVPOTlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HEeWlEPTB;MkeuN{BvVQ>? NW\HR5pzW0GQR1XS
SW837 M2rYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ5Lk[yJI5O MmHYV2FPT0WU
MDA-MB-231 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HnPGlEPTB;MkeuO|ghdk1? NVPuW5F7W0GQR1XS
KYSE-140 M3H4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HuU2lEPTB;MkeuPVEhdk1? M{DyWnNCVkeHUh?=
NOMO-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PQd2lEPTB;MkiuOlghdk1? MoHTV2FPT0WU
GP5d NUTF[mY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXiXZpFUUN3ME2yPE44OiCwTR?= NVjEUHBNW0GQR1XS
COR-L105 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnmT|RKSzVyPUK5MlQzKG6P MoX0V2FPT0WU
LS-411N NXjGPJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjuVJdKSzVyPUK5Mlg5KG6P MmTXV2FPT0WU
NY MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH2TWM2OD1|MD6xPEBvVQ>? MXHTRW5ITVJ?
NCI-H2030 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTPTpgxUUN3ME2zNE41PSCwTR?= NWmxbW4yW0GQR1XS
CCF-STTG1 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fx[WlEPTB;M{GuOFIhdk1? MVvTRW5ITVJ?
NCI-H1703 NIfxS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTYU2tKSzVyPUOxMlc5KG6P MXTTRW5ITVJ?
TUR MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN{LkCzJI5O MorXV2FPT0WU
NOS-1 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzETWM2OD1|Mj60OEBvVQ>? NFjPd3lUSU6JRWK=
A2058 M4K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN{LkizJI5O NEHv[FdUSU6JRWK=
LCLC-103H M1HwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;IWYRVUUN3ME2zN{4zPSCwTR?= NEPQb|lUSU6JRWK=
NCI-H510A M4[2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXZTWM2OD1|Mz6yO{BvVQ>? Mnz0V2FPT0WU
BC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TsUmlEPTB;M{OuO|chdk1? MXnTRW5ITVJ?
SK-CO-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL5TWM2OD1|ND6wNUBvVQ>? Mk\DV2FPT0WU
A673 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTN2LkG3JI5O MVvTRW5ITVJ?
VM-CUB-1 NETqTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPQTWM2OD1|ND62PUBvVQ>? MXrTRW5ITVJ?
HH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL5TWM2OD1|NT6wOkBvVQ>? MUHTRW5ITVJ?
CAL-27 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTN3LkG2JI5O NYToOW1sW0GQR1XS
NEC8 M2ezcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fJbWlEPTB;M{WuN|chdk1? M1;WOXNCVkeHUh?=
BxPC-3 M3X3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD4d4s5UUN3ME2zOk46OSCwTR?= NIm5O|BUSU6JRWK=
SNB75 NYnwO2lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN5LkK0JI5O NF\qUItUSU6JRWK=
NB13 NX\QUJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVZ2lEPTB;M{iuNlMhdk1? NXzPfIx2W0GQR1XS
SK-OV-3 M4XRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjIXIdKSzVyPUO4Mlc1KG6P M4LDR3NCVkeHUh?=
ME-180 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSwNpNbUUN3ME2zPE45KG6P MlnIV2FPT0WU
JiyoyeP-2003 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37hXWlEPTB;M{muN|ghdk1? NIDzbGlUSU6JRWK=
LU-134-A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1Z|ZKSzVyPUSwMlAzKG6P NHK2cHZUSU6JRWK=
LS-123 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXve25KSzVyPUSwMlI5KG6P NHHtSZNUSU6JRWK=
COLO-800 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFywUJBKSzVyPUSwMlU3KG6P M1j5VnNCVkeHUh?=
LB831-BLC NHPkS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonSTWM2OD12MT64OUBvVQ>? NWDS[GFSW0GQR1XS
NCI-H747 NULS[W04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1cmlEPTB;NEKuNlghdk1? M{HkN3NCVkeHUh?=
MZ7-mel NWXKOo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTjTWM2OD12Mj62OkBvVQ>? MVXTRW5ITVJ?
GT3TKB NWnXRm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSxTWM2OD12Mj63NkBvVQ>? MXPTRW5ITVJ?
MOLT-16 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXQSIZrUUN3ME20N{4xPSCwTR?= NUHSfFBMW0GQR1XS
23132-87 NHjaeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDRfGV3UUN3ME20N{4xPSCwTR?= NFq3UmdUSU6JRWK=
PF-382 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD12ND6yNkBvVQ>? M2T5SHNCVkeHUh?=
ES3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR2Lk[gcm0> MorQV2FPT0WU
SW756 NXLVWGx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TMR2lEPTB;NEWuNVQhdk1? MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
water warming
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID